Literature DB >> 31737290

Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer.

Fernando Franco1, Mariano Provencio1.   

Abstract

Entities:  

Year:  2019        PMID： 31737290      PMCID： PMC6837986          DOI： 10.21037/jtd.2019.09.68

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Radical surgical resection after neoadjuvant targeted therapy in non-small cell lung cancer: a single-center retrospective study of 6 cases.

Authors:  Zhenyang Zhang; Jiangbo Lin; Shuai Peng; Wenwei Lin; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

3.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

4.  Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.

Authors:  Eva E Schaake; Ingrid Kappers; Henk E Codrington; Renato A Valdés Olmos; Hendrik J Teertstra; Renée van Pel; Jacobus A Burgers; Harm van Tinteren; Houke M Klomp
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 6.  Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.

Authors:  Eric Lim; Grace Harris; Amit Patel; Iki Adachi; Lyn Edmonds; Fujian Song
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Authors:  Wen-Zhao Zhong; Ke-Neng Chen; Chun Chen; Chun-Dong Gu; Jun Wang; Xue-Ning Yang; Wei-Min Mao; Qun Wang; Gui-Bin Qiao; Ying Cheng; Lin Xu; Chang-Li Wang; Ming-Wei Chen; Xiaozheng Kang; Wanpu Yan; Hong-Hong Yan; Ri-Qiang Liao; Jin-Ji Yang; Xu-Chao Zhang; Qing Zhou; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2019-06-13       Impact factor: 44.544

9.  Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Authors:  Martin Reck; Tony S K Mok; Makoto Nishio; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Anthony Lee; Shelley Coleman; Yu Deng; Marcin Kowanetz; Geetha Shankar; Wei Lin; Mark A Socinski
Journal:  Lancet Respir Med       Date:  2019-03-25       Impact factor: 30.700

Review 10.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.

Authors: 
Journal:  Lancet       Date:  2014-02-25       Impact factor: 79.321
View more
  1 in total

Review 1.  Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.

Authors:  Sara Montemuiño Muñiz; Soraya Marcos Sánchez; Julia Calzas Rodríguez; Beatriz Losada Vila; Esther Llorente Herrero; María Dolores Hisado Díaz; Victoria Valeri-Busto González; Begoña Taboada Valladares; Blanca Vaquero Barrón; Francisco José Marcos Jimenez; Sergio Amor Alonso; Javier Moradiellos; Núria Rodríguez de Dios; Felipe Couñago
Journal:  J Clin Transl Res       Date:  2021-04-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.